Europese Unie - Nederlands - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologica - eylea is geïndiceerd bij volwassenen voor de behandeling van:neovascular (natte) leeftijdsgebonden maculaire degeneratie (amd);slechtziendheid als gevolg van maculair oedeem, secundair aan retinale veneuze occlusie (tak rvo of centrale rvo);visuele handicap vanwege diabetisch macula-oedeem (dme);visuele handicap vanwege bijziend choroidale neovascularisation (bijziend cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologica - lucentis is geïndiceerd bij volwassenen voor:de behandeling van neovascular (natte) leeftijdsgebonden maculaire degeneratie (amd)de behandeling van slechtziendheid als gevolg choroidale neovascularisation (cnv)de behandeling van slechtziendheid als gevolg diabetisch macula-oedeem (dme)de behandeling van slechtziendheid als gevolg van maculair oedeem, secundair aan retinale veneuze occlusie (tak rvo of centrale rvo).

Europese Unie - Nederlands - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanib - natte maculaire degeneratie - ophthalmologica - macugen is geïndiceerd voor de behandeling van neovasculaire (natte) leeftijdsgebonden maculaire degeneratie (amd).

Europese Unie - Nederlands - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologica - visudyne is geïndiceerd voor de behandeling van:volwassenen met exsudatieve (natte) leeftijdsgebonden maculaire degeneratie (amd), met overwegend klassieke subfoveal choroidale neovascularisation (cnv) of;volwassenen met subfoveal choroidale neovascularisation secundair aan pathologische myopie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologica - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologica - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologica - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Europese Unie - Nederlands - EMA (European Medicines Agency)

rotterdam biologics b.v. - bevacizumab - natte maculaire degeneratie - ophthalmologica - treatment of neovascular (wet) age-related macular degeneration (amd).